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Abstract Stroke is a leading cause of serious long-term
disability in adults and is the second leading cause of death
worldwide. Early reperfusion and neuroprotection tech-
niques have been the focus of much effort with the aim of
very acute treatment of the stroke. Targeting different
mechanisms, pharmacological therapies have the potential
to reduce disability in a large fraction of patients who
survive the acute stroke. The brain’s capacity to reorganize
after stroke through plasticity mechanisms can be modu-
lated by pharmacological agents. A number of therapeutic
interventions are under study, including small molecules,
growth factors, and monoclonal antibodies. Recently it has
been shown that the SSRI fluoxetine improved motor
deficit in patients with ischaemic stroke and hemiplegia
which appeared to be independent of the presence of
depression. In this context, it is of major importance to
support innovative research in order to promote the emer-
gence of new pharmacological treatments targeting neu-
rological recovery after stroke, as opposed to acute de-
occlusion and neuroprotection. This paper is the work of a
group of 14 scientists with aim of (1) addressing key areas
of the basic and clinical aspects of human brain plasticity
after stroke and potential pharmacological targets for
recovery, (2) asking questions about the most appropriate
characteristics of clinical trials testing drugs in post stroke
recovery and (3) proposing recommendations for future
clinical trials.
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Introduction
Stroke is a leading cause of serious long-term disability in
the United States in adults and is the second leading cause
of death worldwide [1]. Considerable advances have been
achieved in the past 25 years in terms of stroke primary
and secondary prevention, mainly with the control of
vascular risk factors and with the treatment of the cause.
Early reperfusion and neuroprotection techniques also
have been the focus of much effort with the aim of very
acute treatment of the stroke [2]. During the twentieth
century, preclinical studies identified at least 75 agents as
potentially active that were tested in 178 clinical trials.
Only three of them were positive and only one drug (rtPA)
was registered by the health authorities. Finally the main
gain came from stroke care organizations and stroke units
which were shown to improve stroke mortality and mor-
bidity [3].
Pharmacological therapies have the potential to reduce
disability in a large fraction of patients who survive the
acute stroke [4]. The brain’s capacity to reorganize after
stroke through plasticity mechanisms can be modulated by
pharmacological agents. A number of therapeutic inter-
ventions are under study, including small molecules,
growth factors, other large molecules such as monoclonal
antibodies, or stem cells. Recently the FLAME (fluoxetine
for motor recovery after ischaemic stroke) study showed
that the selective serotonin reuptake inhibitor (SSRI) flu-
oxetine improved motor deficit in patients with ischaemic
stroke and hemiplegia which appeared to be independent of
the presence of depression [5].
In this context, it is of major importance to support
innovative research in order to promote the emergence of
new pharmacological treatments targeting neurological
recovery after stroke, as opposed to acute de-occlusion and
neuroprotection, and at the same time to avoid the mistakes
and pitfalls of past studies [3, 6]. The treatment should be
optimally ‘‘patient, physician and healthcare system
friendly’’. It should be suitable for administration to a large
number of patients, compatible with other treatments like
acute thrombolysis, usable without major technical facili-
ties and acceptable in terms of cost.
This paper is the work of a group of 14 scientists who
participated in a 2012 workshop with aim of (1) addressing
key areas of the basic and clinical aspects of human brain
plasticity after stroke and potential pharmacological targets
for recovery, (2) asking questions about the most appro-
priate characteristics of clinical trials testing drugs in post
stroke recovery and (3) proposing recommendations for
future clinical trials.
Pathophysiology, treatment targets: a rational basis
for future clinical trials
Treatment target differs at the very acute stage of the stroke
and at later phases. Different cellular (metabolic, genetic,
and inflammatory) processes, which are dependent on the
time that has elapsed after stroke onset, play a role in the
final outcome. Early reperfusion techniques aim at limiting
damage and reversing cellular dysfunction. Reperfusion
damage affects the neurovascular unit and includes the
formation of free radicals, vasogenic oedema, blood brain
barrier leakage, leukocyte infiltration and enhanced acti-
vation of microglia. While early reperfusion saves (part or
all of) the penumbra, late reperfusion may be detrimental.
Neuroprotective agents have been investigated in the hope
that they could influence the various complicated pathways
at the level of cell metabolism. None of them have been
shown to be beneficial in randomized clinical trials.
With respect to outcome, we do not know the impact of
the different cellular processes that occur during the first
days after stroke onset. However, they have been described
in basic research and animal experiments. Cellular dys-
function, including selective neuronal death, metabolic
depression, inflammation, blood brain barrier leakage and
axonal growth inhibition, starts almost immediately after
stroke and can affect the salvaged penumbra. Subse-
quently, processes such as secondary expansion of infarc-
tion, programmed apoptosis, neovascularization/
angiogenesis, release of growth factors and neurotoxic
chemokines, neurogenesis and neural stem cell migration,
circuit remodelling, and reorganisation of large-scale neu-
ral networks occur. Laboratory studies suggest that it might
be possible to promote brain plasticity and neurological
recovery by pharmacological or cell-based treatments [7–
9].
Two intertwined mechanisms of brain adaptive or
sometimes maladaptive plasticity are classically
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differentiated. The first is functional plasticity, in the form
of altered neuronal connections, excitability and synaptic
efficacy, which develops spontaneously after the stroke.
This begins within hours of symptom onset and gives way
to heightened use-dependent functional plasticity and
relearning. In animals, these processes are maximally
active around 1 week after stroke, and seem to reach a
plateau by 3–4 weeks, although they can be modulated in
the chronic stage using appropriate intervention. The sec-
ond mechanism is morphological plasticity, which is un-
derpinned by dendritic spine remodelling, axonal sprouting
and synaptogenesis in the initial stage. Finally, although
still unproven, cell genesis may also support recovery of
function in surviving tissues, and is the target of treatments
aimed at neural repair mechanisms (Fig. 1) [10].
Functional recovery after stroke usually evolves over
months and, in some cases, years. Two different behav-
ioural processes are involved in functional recovery after
stroke: (1) restoration of the lost functions and (2) acqui-
sition of new behavioural strategies to circumvent rather
than to restore lost functions. Neuroplasticity is defined as
the ability to adapt neuronal functions and connections at
the molecular, cellular or functional level [11]. Modern
neuroimaging techniques have shown that it can take place
in the perilesional areas and also in remote areas (ipsi- or
contralesional hemisphere or cerebellum). Recovery is a
dynamic process and different regions at different time-
points may support recovery of function. The neuronal
activation in these areas is probably the key factor in
the process of ‘‘use-dependent’’ brain plasticity (Fig. 1)
[12].
It is probable that the intensity of rehabilitation plays an
important role in the process of brain plasticity and it has
been shown that rehabilitation techniques affect brain
reorganization [13]. Rehabilitation after stroke should aim
at reducing impairment and restoring function, and should
also work on adaptive and compensatory strategies.
Rehabilitation should probably start as early as possible,
preferably in the stroke unit and should be guided by a
well-trained multidisciplinary team. Rehabilitation proce-
dures are difficult to quantify and there is no real consensus
on how the techniques should be standardized. More-
over, the qualitative aspect of rehabilitation remains in
Fig. 1 Time course of post stroke recovery (adapted from Wieloch
and Nikolich [10])
Table 1 Main clinical trials testing SSRI in stroke recovering patients
Drug Dose, regimen,
treatment
duration
Number
of
patients
Trial
design
Time of
inclusion
Clinical
outcome
criteria
Other
outcome
criteria
Rehab
program
Main
results
Depression
Dam
et al.
[20]
Fluoxetine
Maprotiline
20 mg o.d.
90 days
48 Parallel
groups (3
groups)
1–6 months HSS None Yes Positive No
Chollet
et al.
[17]
Fluoxetine 20 mg (single
dose)
8 Cross over 15–30 days Finger
tapping
and grip
fMRI Yes Positive No
Zittel
et al.
[19]
Citalopram 40 mg (single
dose)
8 Cross over More than
6 months
Nine hole
peg test
None Yes Positive No
Chollet
et al.
[17]
Citalopram 10 mg o.d.
30 days
20 Parallel
groups (2
groups)
Not
reported
NIHSS TMS Yes Positive No
Chollet
et al.
[5]
Fluoxetine 20 mg o.d.
90 days
118 Parallel
groups (2
groups)
\10 days Fugl
Meyer
score
None Yes Positive No
Mikami
et al.
[21]
Fluoxetine
Nortriptiline
20 mg o.d.
90 days
83 Parallel
groups (3
groups)
Within
6 months
Rankin None Yes Positive Both
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question as no consensus exists for standardized pro-
grammes [14].
Although supported by animal model experiments,
modulating the tone of a specific brain neurotransmitter in
humans is an approach that remains insufficiently studied.
Some studies have used drugs that target multiple brain
monoaminergic receptors (e.g., dopaminergic drugs,
amphetamines). The results of clinical studies are mixed
[15–18].
Studies of serotonergic agents after stroke have shown
improved functional outcomes [19, 20] (Table 1). In the
double-blind, placebo-controlled trial ‘‘fluoxetine for motor
recovery after acute ischemic stroke’’ (FLAME) [5], non-
depressed patients who had an ischemic stroke and had
hemiplegia or hemiparesis were randomized to fluoxetine
(20 mg o.d.) or placebo for 3 months starting 5–10 days
after the onset of stroke. Fugl Meyer Motor Scale (FMMS)
improvement at day 90 was significantly greater and the
number of patients who became independent was higher in
the fluoxetine group. The benefit appears to be independent
of the direct antidepressant action. To date, the FLAME
trial is the most important well designed pharmacological
study to show a positive effect on stroke motor recovery.
Other studies suggest a long lasting effect of the drug [21].
Other therapeutic avenues are currently under investi-
gation [4, 11] with growth factors, other large molecules or
stem cells [22] aiming at repairing the damaged brain.
Some data are already available but until now no positive
effect has been shown.
Stroke is a complex disease and a heterogeneous con-
dition [23]. It is necessary for a clinician to match the right
patients with the right therapy. Cerebrovascular disease
appears to be the end product of many different diseases
and risk factors. Stroke injury, stroke clinical expression
and stroke outcome vary greatly from one patient to the
next. Sometimes these differences are trivial in practice
but, in most cases, they are associated with real differences
in the behavioural sequelae. They influence the approaches
to optimizing the effects of restorative therapies. Bath et al.
[24] recently noted that ‘‘In stroke trials, the impact of
covariates such as age and severity on outcome is typically
much larger than the treatment effect that is being
measured’’.
The pharmaco-economics of a new therapy are non-
medical and non-scientific issues that are not often con-
sidered by researchers but they are a major question in
industrialized countries and probably more so in develop-
ing countries. Studies on cost effectiveness are hampered
by the fact that the published costs of stroke vary consid-
erably with time and place and do not take post-stroke
disorders into account when assessing cost effectiveness
[6]. Low cost care management and low cost treatment are
a major challenge [6, 25].
Questions regarding clinical trials for pharmacological
therapies in stroke recovery
Clinical trials for pharmacological therapies in post-stroke
patients should be hypothesis-driven, and if possible, but-
tressed by data from basic research. Those data should
include not only cellular and molecular mechanisms but
also integrative basic research using animal models. This is
an important aspect to understand, at least partially, the
mechanism of the drug on brain network dysfunction.
Conversely, while such scientific data are essential for the
understanding of the mechanisms of actions, clinical
research often is ahead of the basic science understandings
of specific therapies. The need for clear scientific explana-
tions for the efficacy of a therapy should not hamper the
testing of therapies that have shown promise in patients [26].
What is the appropriate timing for post-stroke recovery
clinical trials?
The key period for recovery is probably within the first
3 months after stroke onset and may well be within the first
2–3 weeks (Fig. 1). It is probably during this period that,
first, the magnitude of potential recovery is at his highest
and, second, treatments are potentially efficient as they can
interact with the spontaneous process of recovery [27, 28].
In order to maximise its effects, pharmacological treat-
ment should therefore be started as soon as possible after
the stroke, probably within one or 2 weeks as supported by
preclinical data. The treatment duration should be
6–12 weeks so as to cover the period of maximal sponta-
neous recovery. It is likely that the treatment duration
could be shorter in patients with mild to moderate deficit in
order to avoid any ceiling effect [29].
Baseline measures should be made at a standardized time
within a limited time window for inclusion, due to sponta-
neous, fast evolution of the patient’s condition. A second
measurement should be made at the end of treatment. An
intermediate measurement can be useful to detect whether a
treatment effect is present if a parameter is suspected to
influence the speed of recovery. A follow-up measure at 6 or
12 months after stroke is important for investigating the
potential long-term benefits. However, long-term measure-
ments can be difficult to interpret as many confounding
factors may have occurred in such a long period of time such
as recurrent stroke or other serious comorbid diseases.
Clinical studies show that recovery may still occur
after 3 months but with lower speed and smaller magni-
tude. Drug treatments and clinical trials should consider
the fact that the expected effect of the intervention will
probably be smaller. Recovery, however, may be longer
in some brain systems, such as those related to cognitive
functions [29].
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What is the target population and sample size?
There are two main advantages to having an identified
target population. First, the variance and, consequently, the
sample size is reduced and the power of the study is
strengthened. Second, the effect of a therapy may be
maximal if the presence of the biological target can be
confirmed. For many of the approaches to restorative
therapy, the intervention is unlikely to help if the main
brain elements targeted by therapy have been destroyed by
the stroke. Similarly, if the brain regions important to
recovery of the behavioural endpoints are severely injured,
such as the corticospinal tract in a study focusing on upper
limb function or gait velocity, effects of a restorative
therapy may be limited. The counterpart is that recruitment
may be slow.
The main idea is to maximize the likelihood that a
patient’s features match those present in the animal models
that demonstrated preclinical therapeutic efficacy. This
issue was raised in an analysis of data from the Phase III
‘‘Everest Trial’’ of epidural motor cortex stimulation [30].
The rodent and primate studies that demonstrated preclin-
ical efficacy all required preserved motor evoked poten-
tials, but the human study did not. While the overall trial
did not find a difference, a post hoc analysis did find that
preserved motor evoked potentials were associated with a
significantly higher rate of clinical benefit.
Non-clinical biomarkers can help to target the popu-
lation or to stratify within the selected population. Serum
or other body fluids/tissues could be used to derive a
measure of relevant biomarkers, such as of inflammatory
mediators or neurotrophin levels [34]. Increasing evi-
dence suggests that genetic variation in systems related
to neural repair is associated with differences in brain
plasticity and stroke recovery [31]. A number of ana-
tomical methods, such as structural multimodal MRI,
may be useful to define patient subpopulations: volume
infarct, extent of injury to a key grey matter region, hand
motor area identification [32], white matter tracts, such
as the corticospinal tract defined using diffusion tensor
tractography [33], voxel based morphometry, cortical
thickness. Other methods such as isotope-based methods
near-infrared spectroscopy, magnetoencephalography and
electroencephalography, transcranial magnetic stimulation
or transcranial current simulation also provide informa-
tion on intracortical and interhemispheric function, as
well as the functional integrity of descending motor
pathways [29].
The choice of method should be guided by the message
of available preclinical and clinical data. Centres should be
selected appropriately.
What are the appropriate criteria to assess recovery
in clinical trials?
Several clinical scales have been used to measure
recovery. Some are very analytical scales that focus on a
single function, e.g. grip strength or finger tapping test,
which measure variation in motor capacities. Other
scales are designed to evaluate neurological deficits
(National Institute of Health Stroke Scale/NIHSS,
FMMS). Additional scales are global functional scales
designed to estimate handicap (modified Rankin Scale—
mRS). No scale is perfect nor does a single scale assess
all the features of a complex disease such as stroke; still,
all are useful in some way to assess recovery. A global
scale like mRS, used once at a certain time point after
stroke, measures the patient’s outcome, i.e. the conse-
quences of recovery on the patient’s life while more
neurological scales used at baseline and later time points,
like FMMS or NIHSS, measure the clinical phenomenon
of recovery over time. However, the main judgement
criteria for any intervention in the field of post-stroke
recovery will consider a global scale designed to eval-
uate changes in the daily life of the patients.
The modified Rankin Scale has good intra- and inter-
observer variability but has also some limitations. Only
six categories are used to assess quality of life (0–1),
independence (2), dependence, walking capacity and
daily activities (3–5). The distance between the six
points is not similar and there is an interaction with
other parameters not strictly measured with mRS (mood,
cognition, environment, etc.). Finally, dependence and
independence can vary with age, activities, cultural
background, cognition and context [36]. On the other
hand, this sort of functional scale also incorporates any
detrimental effects of the drug on extra-neurological
functions.
The choice of the primary outcome criteria should vary
according to the type of clinical trial. Early trials aimed at
proving a concept or a mechanism (phase IIa) might find
that a scale that focuses on a specific neurological deficit to
be appropriate. In that case, global scales can be considered
as secondary criteria. On the other hand, in later trials, a
global scale is necessary to measure the impact of the
intervention on patients’ lives. Other scales (NIHSS,
FMMS, cognitive scales, depression scale, etc.) will be of
interest in confirming the suspected mechanism of action
[26, 35]. Finally, surrogate markers of biological effects,
such as fMRI or TMS, are useful to implement as a sub-
study in order to underpin the mechanisms of action and
correlation with clinical outcome of the pharmacological
agent tested.
J Neurol (2014) 261:1461–1468 1465
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What is the appropriate method to analyze outcome
criteria?
Examples exist in the literature showing that different
results would have been found in the same clinical trial
when other statistical methods had been used to analyse the
data [37].
If we consider mRS, dichotomized end point analysis
has been widely used until now [39]. The principle is to
compare the proportion of patients with mRS 0–2 (for
example) at the end of the treatment between the two
groups. So an ordinal score is changed into a binary system
with a need to determine a cut-off. This can be done with
other scales (Barthel index/BI, NIHSS) with the advantage
of great clinical significance, ease of comprehension and
the capacity to calculate the NNT (number needed to treat).
On the other hand, the choice of the cut-off is something of
a gamble and it is difficult to consider that patients scoring
0–2 or scoring 3–5 on the mRS are in the same category
[39]. Moreover, intermediate data are not included in such
an approach.
The global statistical analysis is a method grouping
together several parameters of post-stroke recovery. The
idea is that no one scale is capable of accounting for all
aspects of a patient’s condition. For example, the quality of
post-stroke recovery could be the result of neurological
deficit, daily living dependence, cognitive status, and
quality of life. The association of several scales allows the
study power to be increased. On the other hand, clinical
significance can be difficult to assess with this technique
and it gives no information on the specificities of the drug’s
action.
The responder analysis (adjusted dichotomous) method,
also called baseline severity analysis, is based on the
concept of response to treatment and has the advantage of
adjusting judgement to the initial severity of the patient’s
condition [26, 35–40]. The question is: has the patient
improved when compared to the initial condition? The
advantage is a more accurate analysis of the treatment
effect, independently of the expected outcome which is
dictated by the topography and extent of the permanent
tissue damage; the difficulty lies in defining what a
responder is (e.g., 50 %).
The shift analysis method is aimed at assessing differ-
ences among treatment groups at each point of the scale
considered. The question is: does the treatment induce a
change of at least one point on the scale? This identifies
improvement and worsening with no necessity to define an
objective for treatment response in advance. The main
difficulty of the method is that the data are difficult to
understand and to interpret. However, the re-analysis of a
number of clinical trials has shown that the shift analysis
may be more effective than a dichotomized analysis
(Fig. 2) [38].
All these methods are potentially appropriate and it is
difficult to choose one of them exclusively. If dichotomized
analysis appears to be the best to show the clinical benefit
of the treatment, we think that it may be used in combi-
nation to other methods.
Conclusion: recommendations for future
pharmacological clinical trials in post-stroke recovery
On the basis of all aspects of stroke recovery, it is possible
to propose some guidelines for future clinical trials of
drugs in order to maximize the ability to detect treatment
effects, if present.
1. Clinical trials should be hypothesis-driven and should
include some understanding of the drug’s mechanism.
They need to be associated with conventional rehabil-
itation procedures.
2. Both the choice and the timing of administration of a
drug intended to improve recovery after stroke should,
as far as possible, be based on evidence from
preclinical studies. Preclinical research policy is
strongly needed in order to build rational hypotheses
and to identify mechanisms of action.
3. Standardization of rehabilitation procedures does not
currently exist and will be difficult to achieve. Indirect
measurements, like the daily intensity of treatment and
the duration of rehabilitation in weeks, should be
implemented in any clinical trial testing therapies that
target recovery after stroke.
4. Selection of the population is a key point as precise
selection can reduce statistical variance and increase
the study’s power. It should be based on clinical
arguments. Biomarkers can also be recorded and used
for pre hoc stratification or in post hoc analysis but
they cannot be considered as primary efficacy criteria.
Patients with confounding factors should be excluded.
The relevant biomarker may be specific for assessing
the responses to the drug that is being tested.
Fig. 2 Statistical analysis of clinical trials. (From Saver et al. [38],
Stroke)
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5. It is useful to differentiate trials investigating recovery
and trials investigating outcome.
• Trials investigating recovery should be used at an
early stage in drug development with the aim of
validating the concept. They should use neurolog-
ical scales (FMMS, NIHSS…) as primary criteria.
They could test a precise hypothesis in a strictly
selected population of patients. Global scales
should be used as secondary criteria.
• Larger trials investigating outcomes should be used
as the ultimate step in drug development. They
should use a global scale as primary criterion and
will need a bigger sample of patients as the
sensitivity of the scale is lower. Currently, the mRS
appears to be the most appropriate global scale.
Other scales (NIHSS, FMMS, cognitive scales,
depression scales, etc.) will be used as secondary
measures of responses. They can focus on the
quantification of the modality-specific effects of
the intervention.
6. Clinical trials should enroll subjects as soon as
possible after stroke, preferably within the first
2 weeks when the preclinical data support this
approach. The treatment duration should cover the
first 3 months after stroke. It should last at least
6 weeks and up to 3 months. Trials investigating
recovery should include measurement of outcome
measures at baseline that are repeated at the end of
treatment. Intermediate measures should be included.
Trials investigating outcome need a clear primary
endpoint at a specified time after stroke. Long-term
follow up (at 6 or 12 months) is potentially useful.
7. In order to augment sensitivity to drug treatment
effects, dichotomized endpoint analysis should be used
alone and in combination with other methods consid-
ering the patient’s initial condition.
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